https://www.avient.com/sites/default/files/2020-05/1.-polyone-ir-presenstation-fermium-research-chemicals-conference.pdf
Microsoft PowerPoint - PolyOne Investor Presentation 5.4.20_v8 • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • P E O P LE P RO D U CT S P LA N E T P E RF O R MAN C E •• •• •• JVs Performance Products & Solutions Distribution Specialty To be the world’s premier provider of specialized polymer materials, services and solutions To be the world’s premier provider of specialized polymer materials, services and sustainable solutions • • • • • • • • • • • • • • 2016 2017 2018 2019 Lightweighting Reduced Material Requirements Improved Recyclability Renewable Energy Applications Eco-conscious Bio-derived Content Reduced Energy Use VOC Reduction $275M $325M $355M $410M 14% Total Annual Growth 9% Organic Annual Growth PolyOne Corporation 33 Adjusted EPS attributable to PolyOne common shareholders is calculated as follows: 2009* 2010* 2011* 2012* 2013* 2014* 2015* 2016** 2017** 2018 2018*** Q1 2019*** 2019 Q1 2020 Net income from continuing operations attributable to PolyOne common shareholders Joint venture equity earnings, after tax Special items, before tax(1) Special items, tax adjustments(1) Adjusted net income from continuing operations attributable to PolyOne common shareholders $ 106.7 $ 152.5 $ 153.4 $ 53.3 $ 94.0 $ 78.0 $ 144.6 $ 166.4 $ 173.5 $ 161.1 $ 87.7 $ 22.4 $ 75.5 $ 33.1 (19.0) (14.7) (3.7) — — — — — — — — — — — (48.7) 24.2 (48.1) 55.1 46.3 164.2 87.6 23.8 32.9 59.5 58.7 12.2 61.7 9.6 (27.2) (96.7) (24.7) (18.9) (13.7) (73.7) (58.7) (15.9) (24.8) (25.3) (25.1) (1.2) (5.9) (1.0) $ 11.8 $ 65.3 $ 76.9 $ 89.5 $ 126.6 $ 168.5 $ 173.5 $ 174.3 $ 181.6 $ 195.3 $ 121.3 $ 33.4 $ 131.3 $ 41.7 Diluted shares 93.4 96.0 94.3 89.8 96.5 93.5 88.7 84.6 82.1 80.4 80.4 78.2 77.7 86.7 Adjusted EPS attributable to PolyOne common shareholders $ 0.13 $ 0.68 $ 0.82 $ 1.00 $ 1.31 $ 1.80 $ 1.96 $ 2.06 $ 2.21 $ 2.43 $ 1.51 $ 0.43 $ 1.69 $ 0.48 * Historical results are shown as presented in prior filings and have not been updated to reflect subsequent changes in accounting principle, discontinued operations or the related resegmentation. ** Pro forma for sale of Designed Structures and Solutions segment (DSS). *** Pro forma for sale of Performance Products and Solutions segment (PP&S).
Reconciliation to Adjusted EPS Excluding Special Items and Impacts of February 2020 Equity Offering Three MonthsEnded March 31, 2020 Net income from continuing operations – GAAP $ 33.1 Special items, after tax(1) 8.6 After tax interest income earned on equity proceeds, included in Interest expense, net (0.7) Adjusted net income excluding special items and impact of interest income on equity proceeds $ 41.0 Diluted weighted-average shares used to compute earnings per common share 86.7 Weighted-average impact of 15.3 million shares issued in February 2020 equity offering (9.3) Diluted weighted-average shares excluding impact of shares issued in February 2020 equity offering 77.4 Adjusted EPS - excluding special items and the net impact of equity offering $ 0.53 Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to PolyOne shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to PolyOne shareholders, excluding special items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/2020-12/excelite-1-page-case-study-putty-knife_0.pdf
Excelite OnePager Putty Knife PUTTY KNIFE MANUFACTURER N O R T H A M E R I C A • Reduce current scrap rate of 30% • Eliminate prominent sink marks • Minimize random short shots • Reduced scrap rate to 1% • Eliminated sink marks • Improved mold fill • Improvement in cell structure increased cell density and dimensional stability during critical cooling time Excelite™ IM Chemical Foaming Additives KEY REQUIREMENTS* WHY AVIENT?
https://www.avient.com/resources/safety-data-sheets?page=4561
Geon(TM) DB5261 Neutral TT Iso Stable
Shipment Notification - under "Material Header" MSDS - labeled as the "Product Number" (in Section 1)
https://www.avient.com/company/policies-and-governance
This statement has been published in accordance with section 54(1) of the Modern Slavery Act 2015 and constitutes the second modern slavery and human trafficking statement of ColorMatrix Europe Limited (“ColorMatrix”) and covers the 2024 financial year.
Global ISO Certificate Library
https://www.avient.com/sites/default/files/2020-12/excelite-1-page-case-study-grab-handle.pdf
Excelite OnePager Grab Handle (2) TIER 1 MOLDER A U T O M O T I V E G R A B H A N D L E • Reduce production cycle times • Achieve processing consistency in chemical foaming additive (CFA) performance • Control dimensional stability and reduce production scrap rates • Lower conversion costs • Improved cycle time by 20% • Achieved additional 2% density reduction • Resulted in a finer cell structure with a higher cell density, significantly improving dispersion and dimensional stability • Maintained Class A finish • Reduced CFA use rate by 80% Excelite™ IM Chemical Foaming Additives KEY REQUIREMENTS* WHY AVIENT?
https://www.avient.com/sites/default/files/2020-07/versaflex-cpap-tubing-film.pdf
Versaflex - CPAP tubing film CPAP TUBING C O R R U G A T E D T U B I N G F I L M • Replacement for polyolefins • Good spring-back • Bondable cuffs • Clear & clean look • Minimize humidity and condensation within the tube • No noticeable odor • FDA, ISO 10993 & USP VI compatible • Provided TPE solution to meet market expectations for improved user comfort & aesthetics • Reduced tube noise and improved drape compliance with new material solution versus polyolefins • Offered solution with improved thermal properties to combat humidity Versaflex™ CL2250 KEY REQUIREMENTS WHY AVIENT?
https://www.avient.com/sites/default/files/2023-11/Versaflex HC -Syringe tip cap-Case study snapshot.pdf
PRE-FILLED SYRINGE COMPANY S Y R I N G E T I P C A P • Excellent sealing performance • No DEHP or natural rubber latex added during processing • Can be sterilized by EtO • Compliant with ISO 10993-4&5 and USP Class VI • Formulated a solution that met rigorous medical application requirements • Leveraged global footprint to ensure supply continuity • Increased process efficiency by replacing previous thermoset material with a TPE Versaflex™ HC Thermoplastic Elastomers KEY REQUIREMENTS WHY AVIENT?
https://www.avient.com/sites/default/files/2021-07/eccoh-optical-cable-sheath-case-study-one-pager.pdf
WIRE &CABLE COMPANY O P T I C A L C A B L E S H E A T H • Excellent resistance to fungi and mildew • Good UV resistance • Meet flame retardant standard IEC 60332-3C • Provided an anti-fungi solution with an ISO 846 rating of 0, showing no growth under microscope • Formulated solution to meet flammability performance demands for IEC60332-2 or GBT 18380.22-2008 compliance • Complied with Biocidal Product Regulation (EU) No528/2012 (BPR) ECCOH™ Thermoplastic Formulation KEY REQUIREMENTS WHY AVIENT?
https://www.avient.com/sites/default/files/2022-11/Versaflex CL-Serum collection cartridge-Application Snapshot.pdf
A LIFE SCIENCE COMPANY S E R U M C O L L E C T I O N C A R T R I D G E • Excellent clarity • Good bonding and peel strength onto PP • Heat resistance • Meet sterilization needs • Easy processing • Formulated transparent Shore 50A TPE with excellent adhesion onto PP and good sealing performance • Met regulatory requirements for USP Class VI and ISO 10993-4,5 • Provided a short lead time and on-site technical service Versaflex™ CL Thermoplastic Elastomers KEY REQUIREMENTS WHY AVIENT?
https://www.avient.com/sites/default/files/2024-07/Versaflex TPE for Orthopedic Sole Insert - Application Snapshot.pdf
ORTHOPEDIC PARTS MANUFACTURER O R T H O P E D I C S O L E I N S E R T • A super soft TPE (